AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announces the publication of an article entitled “Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report".
MRV Research
New class of inhibitory compounds developed to aid melanoma treatments
A University of California, Irvine pharmacology researcher has helped create a class of inhibitory compounds that can strongly enhance the effect of anti-tumor drugs for melanoma.
In-person consults reveal melanomas at an earlier stage
Early-stage melanoma was more likely to be detected during an in-person consult than in an incidental fashion, according to study results.
Researchers studied records from 17,174 consults dermatology consults at the Minneapolis Veterans Affairs Medical Center.
James Allison on the Future of Checkpoint Inhibitors in Melanoma
Immune checkpoint blockade has become a pillar of cancer treatment, says immunotherapy pioneer James Allison, PhD.